Ariad Pharmaceuticals, Inc. Grants Second Commercial License To Its Patented ARGENT(TM) Cell-Signaling Regulation Technology For Development Of New Cancer Therapies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced a non-exclusive, royalty-bearing license agreement to its ARGENT™ cell-signaling regulation technology with CellNexus, LLC to develop and commercialize new cancer therapies. ARIAD will have an equity stake in CellNexus and will receive additional payments based on certain development, regulatory and commercial milestones achieved by CellNexus. Products in the partnership will use ARIAD’s small-molecule dimerizer drug, AP1903, which already has successfully completed a Phase 1 clinical trial.

MORE ON THIS TOPIC